Journal of Clinical Oncology, Vol 21, Issue 4
(February), 2003: 607-614
© 2003 American Society for Clinical Oncology
Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin’s Disease: Report of an Intergroup Trial
David B. Duggan,
Gina R. Petroni,
Jeffrey L. Johnson,
John H. Glick,
Richard I. Fisher,
Joseph M. Connors,
George P. Canellos,
Bruce A. Peterson
From the Department of Medicine, State University of New York Upstate Medical University, Syracuse, and James P. Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY; Cancer and Leukemia Group B Statistical Center, Duke University, Durham, NC; Division of Oncology, University of Minnesota School of Medicine, Minneapolis, MN; University of Pennsylvania Cancer Center and Abramson Family Cancer Research Institute, Philadelphia, PA; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and British Columbia Cancer Agency-Vancouver Cancer Center, Vancouver, British Columbia, Canada.
Address reprint requests to David Duggan, MD, Department of Medicine, State University of New York Upstate Medical University, 750 East Adams St, Syracuse, NY 13210; email: duggand{at}upstate.edu.
Purpose: In a series of trials, doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (MOPP/ABV) have been identified as effective treatments for Hodgkin’s disease. We compared these regimens as initial chemotherapy for Hodgkin’s disease.
Patients and Methods: Adult patients (N = 856) with advanced Hodgkin’s disease were randomly assigned to treatment with ABVD or MOPP/ABV. The major end points were failure-free and overall survival, life-threatening acute toxicities, and serious long-term toxicities, including cardiomyopathy, pulmonary toxicity, myelodysplastic syndromes (MDS), and secondary malignancies.
Results: The rates of complete remission (76% v 80%, P = .16), failure-free survival at 5 years (63% v 66%, P = .42), and overall survival at 5 years (82% v 81%, P = .82) were similar for ABVD and MOPP/ABV, respectively. Clinically significant acute pulmonary and hematologic toxicity were more common with MOPP/ABV (P = .060 and .001, respectively). There was no difference in cardiac toxicity. There were 24 deaths attributed to initial treatment: nine with ABVD and 15 with MOPP/ABV (P = .057). There have been 18 second malignancies associated with ABVD and 28 associated with MOPP/ABV (P = .13). Thirteen patients have developed MDS or acute leukemia: 11 were initially treated with MOPP/ABV, and two were initially treated with ABVD but subsequently received MOPP-containing regimens and radiotherapy before developing leukemia (P = .011).
Conclusion: ABVD and the MOPP/ABV hybrid are effective therapies for Hodgkin’s disease. MOPP/ABV is associated with a greater incidence of acute toxicity, MDS, and leukemia. ABVD should be considered the standard regimen for treatment of advanced Hodgkin’s disease.
Research for CALGB 8952 was supported in part by grants from the National Cancer Institute, Bethesda, MD (CA31946), to the Cancer and Leukemia Group B (Richard L. Schilsky, MD, Chair). Additional grants to participating institutions are listed in the Appendix (available online at www.jco.org).
The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
P. J. Hoskin, L. Lowry, A. Horwich, A. Jack, B. Mead, B. W. Hancock, P. Smith, W. Qian, P. Patrick, B. Popova, et al.
Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244
J. Clin. Oncol.,
November 10, 2009;
27(32):
5390 - 5396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Engert, V. Diehl, J. Franklin, A. Lohri, B. Dorken, W.-D. Ludwig, P. Koch, M. Hanel, M. Pfreundschuh, M. Wilhelm, et al.
Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study
J. Clin. Oncol.,
September 20, 2009;
27(27):
4548 - 4554.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Edwards-Bennett, L. M. Jacks, C. H. Moskowitz, E. J. Wu, Z. Zhang, A. Noy, C. S. Portlock, D. J. Straus, A. D. Zelenetz, and J. Yahalom
Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience
Ann. Onc.,
September 16, 2009;
(2009)
mdp337v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Crump and D. Hodgson
Secondary Breast Cancer in Hodgkin's Lymphoma Survivors
J. Clin. Oncol.,
September 10, 2009;
27(26):
4229 - 4231.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Owadally, M. R. Sydes, J. A. Radford, B. W. Hancock, M. H. Cullen, S. P. Stenning, and P. W. M. Johnson
Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519)
Ann. Onc.,
August 14, 2009;
(2009)
mdp331v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Avigdor, S. Bulvik, I. Levi, E. J. Dann, N. Shemtov, G. Perez-Avraham, A. Shimoni, A. Nagler, I. Ben-Bassat, and A. Polliack
Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma
Ann. Onc.,
July 16, 2009;
(2009)
mdp271v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Numbenjapon, J. Wang, D. Colcher, T. Schluep, M. E. Davis, J. Duringer, L. Kretzner, Y. Yen, S. J. Forman, and A. Raubitschek
Preclinical Results of Camptothecin-Polymer Conjugate (IT-101) in Multiple Human Lymphoma Xenograft Models
Clin. Cancer Res.,
July 1, 2009;
15(13):
4365 - 4373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Brusamolino, A. Bacigalupo, G. Barosi, G. Biti, P. G. Gobbi, A. Levis, M. Marchetti, A. Santoro, P. L. Zinzani, and S. Tura
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up
Haematologica,
April 1, 2009;
94(4):
550 - 565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Mendler and J. W. Friedberg
Salvage Therapy in Hodgkin's Lymphoma
Oncologist,
April 1, 2009;
14(4):
425 - 432.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Federico, S. Luminari, E. Iannitto, G. Polimeno, L. Marcheselli, A. Montanini, A. La Sala, F. Merli, C. Stelitano, S. Pozzi, et al.
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
J. Clin. Oncol.,
February 10, 2009;
27(5):
805 - 811.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Biasoli, P. Franchi-Rezgui, D. Sibon, J. Briere, E. de Kerviler, C. Thieblemont, V. Levy, C. Gisselbrecht, and P. Brice
Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy
Ann. Onc.,
November 1, 2008;
19(11):
1915 - 1920.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Mendler, J. Kelly, S. Voci, D. Marquis, L. Rich, R. M. Rossi, S. H. Bernstein, C. T. Jordan, J. Liesveld, R. I. Fisher, et al.
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma
Ann. Onc.,
October 1, 2008;
19(10):
1759 - 1764.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. A. Doussis-Anagnostopoulou, T. P. Vassilakopoulos, I. Thymara, P. Korkolopoulou, M. K. Angelopoulou, M. P. Siakantaris, S. I. Kokoris, E. M. Dimitriadou, C. Kalpadakis, M. Matzouranis, et al.
Topoisomerase II{alpha} Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma
Clin. Cancer Res.,
March 15, 2008;
14(6):
1759 - 1766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Buchler, J. Bomanji, and S.M. Lee
FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin's disease-a useful tool for monitoring pulmonary toxicity and disease activity
Haematologica,
November 1, 2007;
92(11):
e120 - e121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Carver, C. L. Shapiro, A. Ng, L. Jacobs, C. Schwartz, K. S. Virgo, K. L. Hagerty, M. R. Somerfield, D. J. Vaughn, and for the ASCO Cancer Survivorship Expert Panel
American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects
J. Clin. Oncol.,
September 1, 2007;
25(25):
3991 - 4008.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Gallamini, M. Hutchings, L. Rigacci, L. Specht, F. Merli, M. Hansen, C. Patti, A. Loft, F. Di Raimondo, F. D'Amore, et al.
Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study
J. Clin. Oncol.,
August 20, 2007;
25(24):
3746 - 3752.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Hohaus, M Giachelia, A Di Febo, M Martini, G Massini, B Vannata, F D'Alo', F Guidi, M Greco, F Pierconti, et al.
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma
Ann. Onc.,
August 1, 2007;
18(8):
1376 - 1381.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Bartlett, D Niedzwiecki, J. Johnson, J. Friedberg, K. Johnson, K van Besien, A. Zelenetz, B. Cheson, G. Canellos, and For the Cancer Leukemia Group B
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804
Ann. Onc.,
June 1, 2007;
18(6):
1071 - 1079.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Boleti and G. Mead
ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors
Ann. Onc.,
February 1, 2007;
18(2):
376 - 380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Byrne and J. P. Gockerman
Salvage Therapy in Hodgkin's Lymphoma
Oncologist,
February 1, 2007;
12(2):
156 - 167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Dann, R. Bar-Shalom, A. Tamir, N. Haim, M. Ben-Shachar, I. Avivi, T. Zuckerman, M. Kirschbaum, O. Goor, D. Libster, et al.
Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome
Blood,
February 1, 2007;
109(3):
905 - 909.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Horning
Risk, Cure and Complications in Advanced Hodgkin Disease
Hematology,
January 1, 2007;
2007(1):
197 - 203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ng and P. Mauch
The impact of treatment on the risk of second malignancy after Hodgkin's disease
Ann. Onc.,
December 1, 2006;
17(12):
1727 - 1729.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Travis
The Epidemiology of Second Primary Cancers
Cancer Epidemiol. Biomarkers Prev.,
November 1, 2006;
15(11):
2020 - 2026.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. S. Jhanwar and D. J. Straus
The Role of PET in Lymphoma
J. Nucl. Med.,
August 1, 2006;
47(8):
1326 - 1334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Ferme, N. Mounier, O. Casasnovas, P. Brice, M. Divine, A. Sonet, F. Bouafia, A. Bastard-Stamatoullas, D. Bordessoule, L. Voillat, et al.
Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Blood,
June 15, 2006;
107(12):
4636 - 4642.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson and G. P. Canellos
The cancer and leukemia group B lymphoma committee.
Clin. Cancer Res.,
June 1, 2006;
12(11):
3572s - 3575s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Ansell and J. O. Armitage
Management of Hodgkin Lymphoma
Mayo Clin. Proc.,
March 1, 2006;
81(3):
419 - 426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Yahalom
Don't Throw Out the Baby With the Bathwater: On Optimizing Cure and Reducing Toxicity in Hodgkin's Lymphoma
J. Clin. Oncol.,
February 1, 2006;
24(4):
544 - 548.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Schonfeld, E. S. Gilbert, G. M. Dores, C. F. Lynch, D. C. Hodgson, P. Hall, H. Storm, A. Andersen, E. Pukkala, E. Holowaty, et al.
Acute Myeloid Leukemia Following Hodgkin Lymphoma: A Population-Based Study of 35 511 Patients
J Natl Cancer Inst,
February 1, 2006;
98(3):
215 - 218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Gobbi, C. Broglia, A. Levis, A. La Sala, F. Valentino, T. Chisesi, S. Sacchi, F. Corbella, L. Cavanna, E. Iannitto, et al.
MOPPEBVCAD Chemotherapy with Limited and Conditioned Radiotherapy in Advanced Hodgkin's Lymphoma: 10-Year Results, Late Toxicity, and Second Tumors
Clin. Cancer Res.,
January 15, 2006;
12(2):
529 - 535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Gobbi, A. Levis, T. Chisesi, C. Broglia, U. Vitolo, C. Stelitano, V. Pavone, L. Cavanna, G. Santini, F. Merli, et al.
ABVD Versus Modified Stanford V Versus MOPPEBVCAD With Optional and Limited Radiotherapy in Intermediate- and Advanced-Stage Hodgkin's Lymphoma: Final Results of a Multicenter Randomized Trial by the Intergruppo Italiano Linfomi
J. Clin. Oncol.,
December 20, 2005;
23(36):
9198 - 9207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. W.M. Johnson, J. A. Radford, M. H. Cullen, M. R. Sydes, J. Walewski, A. S. Jack, K. A. MacLennan, S. P. Stenning, S. Clawson, P. Smith, et al.
Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)
J. Clin. Oncol.,
December 20, 2005;
23(36):
9208 - 9218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Carde
The Chemotherapy/Radiation Balance in Advanced Hodgkin's Lymphoma: Overweight Which Side?
J. Clin. Oncol.,
December 20, 2005;
23(36):
9058 - 9062.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Martin, K. M. Ristow, T. M. Habermann, J. P. Colgan, T. E. Witzig, and S. M. Ansell
Bleomycin Pulmonary Toxicity Has a Negative Impact on the Outcome of Patients With Hodgkin's Lymphoma
J. Clin. Oncol.,
October 20, 2005;
23(30):
7614 - 7620.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Connors
State-of-the-Art Therapeutics: Hodgkin's Lymphoma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6400 - 6408.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Engert, V. Ballova, H. Haverkamp, B. Pfistner, A. Josting, E. Duhmke, K. Muller-Hermelink, and V. Diehl
Hodgkin's Lymphoma in Elderly Patients: A Comprehensive Retrospective Analysis From the German Hodgkin's Study Group
J. Clin. Oncol.,
August 1, 2005;
23(22):
5052 - 5060.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Meyer, M. K. Gospodarowicz, J. M. Connors, R. G. Pearcey, A. Bezjak, W. A. Wells, B. F. Burns, J. N. Winter, S. J. Horning, A. R. Dar, et al.
Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin's Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group
J. Clin. Oncol.,
July 20, 2005;
23(21):
4634 - 4642.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Hohaus, A. Di Ruscio, A. Di Febo, G. Massini, F. D'Alo', F. Guidi, G. Mansueto, M. T. Voso, and G. Leone
Glutathione S-transferase P1 Genotype and Prognosis in Hodgkin's Lymphoma
Clin. Cancer Res.,
March 15, 2005;
11(6):
2175 - 2179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Grann and V. R. Grann
The Case for Randomized Trials in Cancer Treatment: New Is Not Always Better
JAMA,
February 23, 2005;
293(8):
1001 - 1003.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Ballova, J.-U. Ruffer, H. Haverkamp, B. Pfistner, H. K. Muller-Hermelink, E. Duhmke, P. Worst, M. Wilhelmy, R. Naumann, M. Hentrich, et al.
A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)
Ann. Onc.,
January 1, 2005;
16(1):
124 - 131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Connors
Evolving Approaches to Primary Treatment of Hodgkin Lymphoma
Hematology,
January 1, 2005;
2005(1):
239 - 244.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rueda Dominguez, A. Marquez, J. Guma, M. Llanos, J. Herrero, M. A. de las Nieves, J. Miramon, and E. Alba
Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study
Ann. Onc.,
December 1, 2004;
15(12):
1798 - 1804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Bonadonna, V. Bonfante, S. Viviani, A. Di Russo, F. Villani, and P. Valagussa
ABVD Plus Subtotal Nodal Versus Involved-Field Radiotherapy in Early-Stage Hodgkin's Disease: Long-Term Results
J. Clin. Oncol.,
July 15, 2004;
22(14):
2835 - 2841.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. P. Canellos, D. Duggan, J. Johnson, and D. Niedzwiecki
How Important Is Bleomycin in the Adriamycin + Bleomycin + Vinblastine + Dacarbazine Regimen?
J. Clin. Oncol.,
April 15, 2004;
22(8):
1532 - 1533.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. P. Aleman, N. S. Russell, H. Bartelink, and F. E. van Leeuwen
Re: Radiation Therapy in the Treatment of Hodgkin's Disease--Do You See What I See?
J Natl Cancer Inst,
February 4, 2004;
96(3):
235 - 236.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sieber, H. Tesch, B. Pfistner, U. Rueffer, U. Paulus, R. Munker, R. Hermann, G. Doelken, P. Koch, J. Oertel, et al.
Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial
Ann. Onc.,
February 1, 2004;
15(2):
276 - 282.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. M. Ghobrial, R. C. Wolf, D. L. Pereira, R. Fonseca, W. L. White, J. P. Colgan, T. M. Habermann, D. J. Inwards, S. N. Markovic, S. M. Ansell, et al.
Therapeutic Options in Patients With Lymphoma and Severe Liver Dysfunction
Mayo Clin. Proc.,
February 1, 2004;
79(2):
169 - 175.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. l. Maignan, B. Desablens, V. Delwail, M. Dib, C. Berthou, M. Vigier, C. Ghandour, S. Atmani, P. Casassus, H. Maisonneuve, et al.
Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial
Blood,
January 1, 2004;
103(1):
58 - 66.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Baetz, A. Belch, S. Couban, K. Imrie, J. Yau, R. Myers, K. Ding, N. Paul, L. Shepherd, J. Iglesias, et al.
Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group
Ann. Onc.,
December 1, 2003;
14(12):
1762 - 1767.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Connors
Hodgkin's Lymphoma: The Hazards of Success
J. Clin. Oncol.,
September 15, 2003;
21(18):
3388 - 3390.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M.P. Aleman, J. M.M. Raemaekers, U. Tirelli, R. Bortolus, M. B. van 't Veer, M. L.M. Lybeert, J. J. Keuning, P. Carde, T. Girinsky, R. W.M. van der Maazen, et al.
Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma
N. Engl. J. Med.,
June 12, 2003;
348(24):
2396 - 2406.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Diehl
Advanced Hodgkin's Disease: ABVD Is Better, Yet Is Not Good Enough!
J. Clin. Oncol.,
February 15, 2003;
21(4):
583 - 585.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Diehl, H. Stein, M. Hummel, R. Zollinger, and J. M. Connors
Hodgkin's Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease
Hematology,
January 1, 2003;
2003(1):
225 - 247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
